https://www.globenewswire.com/news-release/2018/10/25/1626784/0/en/Axovant-Announces-Dosing-of-First-Patient-in-Clinical-Study-of-AXO-Lenti-PD-a-Novel-Gene-Therapy-for-Patients-With-Parkinson-s-Disease.html
Axovant Announces Dosing of First Patient in Clinical Study
Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON),...
first patientaxovantannouncesdosingclinical
https://www.biospace.com/axovant-gene-therapies-to-present-at-the-2020-jefferies-global-virtual-healthcare-conference
Axovant Gene Therapies to Present at the 2020 Jefferies Global Virtual Healthcare Conference -...
May 28, 2020 - Axovant Gene Therapies, Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that...
axovant gene therapies
https://robinhood.com/us/en/stocks/AXGT/
Axovant Gene Therapies: AXGT Stock Price Quote & News | Robinhood
You can watch AXGT and buy and sell other stocks, ETFs, and their options commission-free on Robinhood. Change the date range, see whether others are buying or...
axovant gene therapiesstock price quotenewsrobinhood